JP7705963B2 - トリアジン誘導体およびがんの処置におけるその使用 - Google Patents

トリアジン誘導体およびがんの処置におけるその使用 Download PDF

Info

Publication number
JP7705963B2
JP7705963B2 JP2023572751A JP2023572751A JP7705963B2 JP 7705963 B2 JP7705963 B2 JP 7705963B2 JP 2023572751 A JP2023572751 A JP 2023572751A JP 2023572751 A JP2023572751 A JP 2023572751A JP 7705963 B2 JP7705963 B2 JP 7705963B2
Authority
JP
Japan
Prior art keywords
methyl
mmol
equiv
triazin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023572751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522494A5 (enExample
JP2024522494A (ja
Inventor
ブッシュ，レア・オレリー
グーバ，ヴォルフガング
ヤーシュケ，ゲオルク
メッシュ，ステファニー・カタリナ
パティニー－アダム，アンジェリーク
シュナイダー，クリスティアン
シュタイナー，サンドラ
トストルフ，アンドレアス・ミシェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024522494A publication Critical patent/JP2024522494A/ja
Priority to JP2025051003A priority Critical patent/JP2025098157A/ja
Publication of JP2024522494A5 publication Critical patent/JP2024522494A5/ja
Application granted granted Critical
Publication of JP7705963B2 publication Critical patent/JP7705963B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023572751A 2021-06-04 2022-06-02 トリアジン誘導体およびがんの処置におけるその使用 Active JP7705963B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025051003A JP2025098157A (ja) 2021-06-04 2025-03-26 トリアジン誘導体およびがんの処置におけるその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21177660 2021-06-04
EP21177660.4 2021-06-04
EP21188639 2021-07-30
EP21188639.5 2021-07-30
EP21215875 2021-12-20
EP21215875.2 2021-12-20
PCT/EP2022/064995 WO2022253936A1 (en) 2021-06-04 2022-06-02 Triazine derivatives and their use in the treatment of cancer.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025051003A Division JP2025098157A (ja) 2021-06-04 2025-03-26 トリアジン誘導体およびがんの処置におけるその使用

Publications (3)

Publication Number Publication Date
JP2024522494A JP2024522494A (ja) 2024-06-21
JP2024522494A5 JP2024522494A5 (enExample) 2025-04-03
JP7705963B2 true JP7705963B2 (ja) 2025-07-10

Family

ID=82115763

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023572751A Active JP7705963B2 (ja) 2021-06-04 2022-06-02 トリアジン誘導体およびがんの処置におけるその使用
JP2025051003A Pending JP2025098157A (ja) 2021-06-04 2025-03-26 トリアジン誘導体およびがんの処置におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025051003A Pending JP2025098157A (ja) 2021-06-04 2025-03-26 トリアジン誘導体およびがんの処置におけるその使用

Country Status (23)

Country Link
US (3) US20240132471A1 (enExample)
EP (1) EP4347571B1 (enExample)
JP (2) JP7705963B2 (enExample)
KR (1) KR20240019083A (enExample)
AR (1) AR126053A1 (enExample)
AU (1) AU2022287224A1 (enExample)
BR (1) BR112023025318A2 (enExample)
CA (1) CA3216026A1 (enExample)
CL (1) CL2023003491A1 (enExample)
CO (1) CO2023016212A2 (enExample)
CR (1) CR20230566A (enExample)
DK (1) DK4347571T3 (enExample)
ES (1) ES3072832T3 (enExample)
FI (1) FI4347571T3 (enExample)
HR (1) HRP20260777T1 (enExample)
IL (1) IL307201A (enExample)
LT (1) LT4347571T (enExample)
MA (1) MA64830B1 (enExample)
MX (1) MX2023013998A (enExample)
PE (1) PE20240928A1 (enExample)
RS (1) RS68198B1 (enExample)
SM (1) SMT202600264T1 (enExample)
WO (1) WO2022253936A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025098157A (ja) * 2021-06-04 2025-07-01 エフ． ホフマン－ラ ロシュ アーゲー トリアジン誘導体およびがんの処置におけるその使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
MX2024008548A (es) * 2022-01-07 2024-07-19 Transthera Sciences Nanjing Inc Inhibidor del inflamosoma nlrp3 y uso del mismo.
JP2025523930A (ja) * 2022-07-21 2025-07-25 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害剤
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
US20260167637A1 (en) * 2022-11-04 2026-06-18 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and use thereof
JP2025540202A (ja) * 2022-12-07 2025-12-11 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害のモジュレーターとしての新規化合物
EP4683918A1 (en) * 2023-03-20 2026-01-28 Insilico Medicine IP Limited Nlrp3 inflammasome inhibitors and uses thereof
JP2026509587A (ja) * 2023-03-23 2026-03-19 成都▲ざ▼▲霊▼生物医▲薬▼科技有限公司 トリアジン化合物およびその使用
CN120958000A (zh) * 2023-04-19 2025-11-14 豪夫迈·罗氏有限公司 噁唑并[4,5-b]吡嗪和噁唑并[4,5-b]吡啶衍生物作为nlrp3抑制剂用于治疗例如炎症性疾病
JP2026514799A (ja) * 2023-04-19 2026-05-13 エフ． ホフマン－ラ ロシュ アーゲー 炎症性疾患の処置のためのｎｌｐｒ３阻害剤としての５－［５－（２－ヒドロキシフェニル）オキサゾロ［４，５－ｂ］ピリジン－２－イル］ピペリジン－２－オン誘導体
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
CN121586712A (zh) * 2023-07-28 2026-02-27 豪夫迈·罗氏有限公司 新颖化合物
WO2025046419A1 (ko) * 2023-08-25 2025-03-06 제일약품주식회사 Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
WO2025252772A1 (en) * 2024-06-06 2025-12-11 F. Hoffmann-La Roche Ag Triazine derivatives
WO2026046981A1 (en) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol
WO2026067453A1 (en) * 2024-09-25 2026-04-02 Insilico Medicine Ip Limited Novel compounds as nlrp3 inflammasome inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020234715A1 (en) 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001425A (es) * 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
BR112020019373A2 (pt) * 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
TW202231281A (zh) 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
EP4289823A4 (en) 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
EP4347571B1 (en) * 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
CN115433163A (zh) 2021-06-05 2022-12-06 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
PL4363406T3 (pl) 2021-07-02 2026-01-05 Astrazeneca Ab Inhibitory inflamasomu nlrp3
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
MX2024008548A (es) 2022-01-07 2024-07-19 Transthera Sciences Nanjing Inc Inhibidor del inflamosoma nlrp3 y uso del mismo.
KR20250005125A (ko) 2022-03-25 2025-01-09 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체
CN120152974A (zh) 2022-10-26 2025-06-13 天维生物制药有限公司 缩环哒嗪衍生物
CN115621720B (zh) * 2022-10-27 2026-07-07 永道射频技术股份有限公司 一种应用于rfid读写器的全息超材料阵列天线
US20260167637A1 (en) 2022-11-04 2026-06-18 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and use thereof
US20260200914A1 (en) 2022-12-28 2026-07-16 Astrazeneca Ab Nlrp3 inflammasome inhibitors
WO2024169858A1 (zh) 2023-02-17 2024-08-22 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020234715A1 (en) 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSUCHIYA, Takashi et al.，Reaction of 1,2,4-Triazine 1-Oxides with Benzyne: Formation of 1,3-Benzoxazepine and 1,3,5,6-Benzoxatriazonine Derivatives，HETEROCYCLES，1996年，Vol. 43，No. 10，p. 2091，DOI: 10.3987/COM-96-7552

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025098157A (ja) * 2021-06-04 2025-07-01 エフ． ホフマン－ラ ロシュ アーゲー トリアジン誘導体およびがんの処置におけるその使用

Also Published As

Publication number Publication date
AU2022287224A1 (en) 2023-09-21
CL2023003491A1 (es) 2024-05-24
EP4347571A1 (en) 2024-04-10
CA3216026A1 (en) 2022-12-08
AR126053A1 (es) 2023-09-06
MA64830B1 (fr) 2026-06-30
US12421209B2 (en) 2025-09-23
WO2022253936A1 (en) 2022-12-08
CO2023016212A2 (es) 2023-12-11
CR20230566A (es) 2024-01-22
RS68198B1 (sr) 2026-06-30
BR112023025318A2 (pt) 2024-02-27
HRP20260777T1 (hr) 2026-08-14
TW202313577A (zh) 2023-04-01
JP2024522494A (ja) 2024-06-21
US20240132471A1 (en) 2024-04-25
MX2023013998A (es) 2023-12-11
SMT202600264T1 (it) 2026-07-16
KR20240019083A (ko) 2024-02-14
JP2025098157A (ja) 2025-07-01
EP4347571B1 (en) 2026-04-22
FI4347571T3 (fi) 2026-06-17
US20250276958A1 (en) 2025-09-04
DK4347571T3 (da) 2026-06-29
ES3072832T3 (en) 2026-07-06
US20250197370A1 (en) 2025-06-19
LT4347571T (lt) 2026-07-10
IL307201A (en) 2023-11-01
PE20240928A1 (es) 2024-04-30

Similar Documents

Publication Publication Date Title
US12421209B2 (en) Compounds
US20240208928A1 (en) Novel compounds
US20240409553A1 (en) Heterocyclic nlrp3 inhibitors
JP2025537238A (ja) Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
JP2025519226A (ja) 新規化合物
JP2025540258A (ja) Ｎｌｒｐ３の阻害剤
TW202434581A (zh) 新穎化合物
JP2025537237A (ja) Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
JP2025523930A (ja) Ｎｌｒｐ３阻害剤
CN117460718A (zh) 三嗪衍生物及其在癌症的治疗中的用途
RU2861618C2 (ru) Триазиновые производные и их применение в лечении рака
EA052779B1 (ru) Триазиновые производные и их применение в лечении рака
EP4698537A1 (en) 5-[5-(2-hydroxyphenyl)oxazolo[4,5-b]pyridin-2-yl]piperidin-2-one derivatives as nlpr3 inhibitors for the treatment of inflammatory diseases
HK40101872A (en) Triazine derivatives and their use in the treatment of cancer
HK40122993A (en) Inhibitors of nlrp3
HK40128712A (en) Oxazolo[4,5-b]pyrazine and oxazolo[4,5-b]pyridine derivatives as nlrp3 inhibitors for the treatment of e.g. inflammatory diseases
HK40111084A (en) Heterocyclic nlrp3 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250326

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250630

R150 Certificate of patent or registration of utility model

Ref document number: 7705963

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150